← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Eli Lilly LLY $1.12T	3,929	+14	+0.4%	$689B
2	2 Pfizer PFE $169B	2,940	-65	-2%	$95.2B
3	3 Amgen AMGN $234B	2,935	+73	+3%	$134B
4	4 McKesson MCK $117B	1,758	+84	+5%	$74.1B
5	5 Becton Dickinson BDX $52.2B	1,616	-15	-0.9%	$59.6B
6	6 Novo Nordisk NVO $171B	1,533	-134	-8%	$22.5B
7	7 Regeneron Pharmaceuticals REGN $81.4B	1,293	-28	-2%	$59.1B
8	8 AstraZeneca AZN $257B	1,253	+32	+3%	$37.3B
9	9 ResMed RMD $33.6B	886	+14	+2%	$21.1B
10	10 Conagra Brands CAG $6.91B	839	-14	-2%	$11B
11	11 West Pharmaceutical WST $27B	715	-33	-4%	$15.6B
12	12 Lamb Weston LW $7.38B	634	-70	-10%	$7.15B
13	13 DaVita DVA $12B	598	+1	+0.2%	$10.9B
14	14 Teva Pharmaceutical Industries Limited TEVA $48.4B	563	-22	-4%	$11B
15	15 BellRing Brands BRBR $1.1B	506	+3	+0.6%	$9.37B
16	16 Hims & Hers Health HIMS $6.55B	431	+36	+9%	$4.73B
17	17 DELISTED WK Kellogg Co KLG	395	-5	-1%	$1.62B
18	18 Viking Therapeutics VKTX $3.2B	373	-36	-9%	$1.88B
19	19 Embecta EMBC $355M	367	-1	-0.3%	$728M
20	20 Inspire Medical Systems INSP $1.99B	363	+5	+1%	$5.46B
21	21 Madrigal Pharmaceuticals MDGL $10.4B	321	+38	+13%	$7.85B
22	22 Biohaven BHVN $1.63B	266	+10	+4%	$2.22B
23	23 MannKind Corp MNKD $977M	257	+13	+5%	$888M
24	24 Opko Health OPK $1.14B	255	+20	+9%	$401M
25	25 Dr. Reddy's Laboratories RDY $10.9B	246	-2	-0.8%	$1.45B